Conjunctival Melanoma: Features and Outcomes Based on the Fitzpatrick Skin Type in 540 Patients at a Single Ocular Oncology Center.
Journal
Ophthalmic plastic and reconstructive surgery
ISSN: 1537-2677
Titre abrégé: Ophthalmic Plast Reconstr Surg
Pays: United States
ID NLM: 8508431
Informations de publication
Date de publication:
Historique:
pubmed:
7
3
2020
medline:
19
3
2021
entrez:
6
3
2020
Statut:
ppublish
Résumé
To determine the association of Fitzpatrick skin type (FST) with conjunctival melanoma. Retrospective case series of 540 patients with conjunctival melanoma to assess clinical features and outcomes per FST. The FST was Type I (n = 126, 23%), II (n = 337, 62%), III (n = 56, 10%), IV (n = 8, 2%), V (n = 12, 2%), and VI (n = 1, <1%). A comparison (FST I vs. II vs. III, IV, V, and VI) revealed Types I and II associated with older mean patient age (63.9 vs. 60.7 vs. 51.1 years, p < 0.001), greater percentage of female patients (68% vs. 44% vs. 42%, p < 0.001), lower frequency of complexion associated melanosis (1% vs. 2% vs. 13%, p < 0.001), smaller tumor thickness (2.1 vs. 2.8 vs. 3.6 mm, p = 0.01), and less eyelid involvement (13% vs. 13% vs. 28%, p = 0.02). Kaplan-Meier estimates for 5-year risk showed no difference by Types for visual acuity loss ≥3 lines, local tumor recurrence, exenteration, metastasis, or death. Most patients with conjunctival melanoma show FST I or II, and this demonstrated no association with 5-year rate of vision loss, tumor recurrence, exenteration, metastasis, or death.
Identifiants
pubmed: 32134771
doi: 10.1097/IOP.0000000000001624
pii: 00002341-202009000-00012
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
490-496Références
Fitzpatrick TB. Soleil et peau [Sun and skin]. Journal de Médecine Esthétique (French) 1975;2:33–34.
Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988;124:869–871.
Agin PP, Desrochers DL, Sayre RM. The relationship of immediate pigment darkening to minimal erythemal dose, skin type, and eye color. Photodermatol 1985;2:288–294.
Ward WH, Lambreton F, Goel N, et al. Ward WH, Farma JM. Clinical presentation and staging of melanoma. In Cutaneous Melanoma: Etiology and Therapy. 2017:Brisbane, Australia: Codon Publications, 79–90.
Barbini P, Cevenini G, Rubegni P, et al. Instrumental measurement of skin colour and skin type as risk factors for melanoma: a statistical classification procedure. Melanoma Res 1998;8:439–447.
Elwood JM, Gallagher RP, Hill GB, et al. Pigmentation and skin reaction to sun as risk factors for cutaneous malignant melanoma: Western Canada Melanoma Study. Br. Med. J 1984:288:99–102.
Sitek A, Rosset I, Żądzińska E, et al. Skin color parameters and Fitzpatrick phototypes in estimating the risk of skin cancer: a case-control study in the Polish population. J Am Acad Dermatol 2016;74:716–723.
Eide MJ, Weinstock MA. Association of UV index, latitude, and melanoma incidence in nonwhite populations: US surveillance, epidemiology, and end results (SEER) program, 1992–2001. Arch Dermatol 2005;141:477–481.
Sunscreen drug products for over-the-counter human drugs: proposed safety, effective, and labeling conditions. Federal Register 1978;43:38206–38207.
Shields CL, Markowitz JS, Belinsky I, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology 2011;118:389–395.e1–2.
Rhodes AR, Weinstock MA, Fitzpatrick TB, et al. Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA 1987;258:3146–3154.
Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for melanoma: a meta-analysis of pigmentary characteristics and freckling. Int J Cancer 2010;127:2430–2445.
Mitra D, Luo X, Morgan A, et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 2012;491:449–453.
Del Bino S, Duval C, Bernerd F. Clinical and biological characterization of skin pigmentation diversity and its consequences on UV impact. Int J Mol Sci 2018,19:2668–2732.
Yu GP, Hu DN, McCormick S, et al. Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol 2003;135:800–806.
Tuomaala S, Kivelä T. Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol 2003;136:1189–1190; author reply 1190.
Shields CL, Shields JA, Gündüz K, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol 2000;118:1497–1507.
Damato B, Coupland SE. An audit of conjunctival melanoma treatment in liverpool. Eye (Lond) 2009;23:801–809.